NEJM publishes Lyxumia (lixisenatide) results of CV outcomes trial in type 2 diabetes patients with ACS- Sanofi

The New England Journal of Medicine has published the data from a cardiovascular outcomes trial, ELIXA , of Sanofi's GLP- Lyxumia (lixisenatide), and the positive side is that the drug did not raise the rate of major cardiovascular events in patients with acute coronary syndrome but it did not lower the rate either. Results published in the NEJM show that 406 Lyxumia patients, being 13.4% recorded a heart attack or stroke, were hospitalized for unstable angina, or died of cardiovascular causes, compared with 399 patients on placebo, or 13.2%. There were no significant differences in the rate of hospitalization for heart failure, and Lyxumia did not increase serious side effects such as pancreatitis.

For comparison, the SGLT-2 inhibitor, Jardiance, from Eli Lilly and Boehringer Ingelheim reduced the combined risk of heart attack, stroke, and death from cardiovascular causes by 14% in high-risk diabetes patients.